Bavencio (avelumab)

Numéro de dossier de l’APP: 21433
État des négociations:
Concluded with an LOI
Indication(s):
Indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy
Promoteur/fabricant:
EMD Serono a Division of EMD Inc. Canada
Numéro de projet de l’ACMTS:
PC0225
Lettre-contrat de l’APP:
Conclusion du processus de négociation: